辉瑞(PFE.US)两款三抗在中国启动2期临床治疗特应性皮炎

智通财经07-24 16:31

智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，辉瑞(PFE.US)在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。

特应性皮炎(AD)是一种常见的慢性、复发性、炎症性皮肤病。IL-4和IL-13是AD发病的重要细胞因子，在AD的发生发展中起着关键作用。

辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2453707882?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-24 16:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453707882","market":"hk","top_or_hot":-1,"title":"辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎","media":"智通财经","content":"<html><body><p>智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。</p><p><img src=\"https://img.zhitongcaijing.com/image/20240724/1721809966998891.png?x-oss-process=image/format,jpg/quality,Q_90\" title=\"1721809966998891.png\"/></p><p>特应性皮炎(AD)是一种常见的慢性、复发性、炎症性皮肤病。IL-4和IL-13是AD发病的重要细胞因子，在AD的发生发展中起着关键作用。</p><p>辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2024-07-24 16:31</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。</p><p><img src=\"https://img.zhitongcaijing.com/image/20240724/1721809966998891.png?x-oss-process=image/format,jpg/quality,Q_90\" title=\"1721809966998891.png\"/></p><p>特应性皮炎(AD)是一种常见的慢性、复发性、炎症性皮肤病。IL-4和IL-13是AD发病的重要细胞因子，在AD的发生发展中起着关键作用。</p><p>辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1154951.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1883839398.USD","symbol_name":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1154951.html","article_id":"2453707882","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453707882","pubTimestamp":1721809919,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，辉瑞在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。特应性皮炎是一种常见的慢性、复发性、炎症性皮肤病。辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4592":"伊斯兰概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4581":"高盛持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"Two tertiary antibodies from Pfizer (PFE.US) launch phase 2 clinical trials for atopic dermatitis in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，辉瑞(PFE.US)在国内登记了一项Ⅱ期临床试验，以评估PF-07275315和PF-07264660在中度至重度特应性皮炎成人受试者中的疗效和安全性。其中，PF-07275315是一款靶向IL-4×IL-13×TSLP的三特异性抗体，PF-07264660是一款靶向IL-4×IL-13×IL-33的三特异性抗体。特应性皮炎(AD)是一种常见的慢性、复发性、炎症性皮肤病。IL-4和IL-13是AD发病的重要细胞因子，在AD的发生发展中起着关键作用。辉瑞拟开发这两款三抗药物用于治疗特应性皮炎适应症。在海外，这两款在研新药此前已进入2期临床试验阶段。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453707882"}

辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎

精彩评论

辉瑞(PFE.US)两款三抗在中国启动2期临床治疗特应性皮炎